Abbott Laboratories (ABT) stock has been underperforming when compared to its competitors on certain days. Despite strong Q2 2024 earnings and increased yearly guidance, the stock hasn't resonated positively in the market. ABT's dividends and robust fundamentals have continued to attract many investors, including hedge funds. The company continues to secure its position in the market with its diversification and the recent expansion of its Pure Bliss product line for infant nutrition. However, the company also tackled various challenges including a decline in COVID-19 testing revenue and lawsuits. One ongoing trial verdict caused the company's stocks to slide, even affecting competitor Reckitt Benckiser. Insiders at ABT have also sold a significant amount of stock recently. On the positive side, ABT achieved FDA approval for its aspirin-free HeartMate 3 regimen and received U.S. clearance to enter the obesity arena. Executive Vice Presidents Hubert Allen and Lisa Earnhardt sold significant shares, and while this may seem a bearish move, ABT is still considered a strong healthcare stock for long-term dividend growth investors.
Abbott Laboratories ABT News Analytics from Wed, 03 Jan 2024 08:00:00 GMT to Fri, 30 Aug 2024 19:32:06 GMT -
Rating -1
- Innovation 6
- Information 8
- Rumor -2
